Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
Generic Copaxone may not gut Teva’s earnings if the drugmaker continues to convert users to its latest formulation. “’We may have failed to understand just how comprehensive Teva’s patient outreach ...
Revenue from Copaxone has yet to fall dramatically following this year's approval of a generic version of the widely used MS therapy. Targeting a top seller Teva's Copaxone is a daily injection ...
NEW YORK, Dec 3 (Reuters) - Teva Pharmaceutical Industries Ltd's Copaxone reduced the risk of patients developing multiple sclerosis after they showed an initial sign of the central nervous system ...
LONDON (Reuters) - Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions ...
Shares of Teva Pharmaceutical Industries LimitedTEVA were down around 4% on Tuesday, as another generic version of its blockbuster multiple sclerosis injection, Copaxone was launched earlier than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results